St. Peter's Hospital introduces an AI-based cerebral aneurysm analysis system
Page information
St. Peter's Hospital 26-08-24 09:37Main content
St. Peter's Hospital has introduced an artificial intelligence (AI)-based program that analyzes the risk of developing a cerebral aneurysm from health screening results alone, further strengthening its system for the early detection of cerebrovascular disease.
The hospital announced on the 24th that it has introduced ANRISK®, from medical AI company Thalos, which estimates the risk of developing a cerebral aneurysm using basic health screening information alone, without a separate cerebrovascular imaging test.
The program comprehensively analyzes blood test values such as hemoglobin, fasting blood glucose and total cholesterol, physical measurements such as weight and blood pressure, and questionnaire data including family history and smoking status.
The analysis is presented as a score from 0 to 100 broken down into five risk groups, and the main factors affecting the risk level are provided alongside it in order of contribution.
Whereas existing cerebrovascular AI technologies have mainly assisted in reading images that have already been taken, this program focuses on identifying in advance, before the imaging stage, those who need a detailed examination.
It is not intended to replace imaging studies themselves or to make a final diagnosis, however; it serves as key reference material for judging whether detailed examination is needed.
St. Peter's Hospital also focused on building a system for prompt referral to care after the analysis, since screening for at-risk groups has to lead to actual detailed examination and treatment for early detection to be effective.
The hospital is equipped with advanced imaging systems including 3.0T MRI and 640-channel MDCT, so patients identified as high-risk can undergo a detailed cerebrovascular examination on site immediately to determine whether a cerebral aneurysm is present and its location and size.
Yoon, Kangjun, President of St. Peter's Hospital, said, “With the introduction of this AI solution, we have completed an in-hospital process in which screening information flows seamlessly into detailed examination and treatment.”
He added, “We will continue to advance our clinical capabilities so that we can not only treat disease after onset but also prevent it in advance.”
The hospital announced on the 24th that it has introduced ANRISK®, from medical AI company Thalos, which estimates the risk of developing a cerebral aneurysm using basic health screening information alone, without a separate cerebrovascular imaging test.
The program comprehensively analyzes blood test values such as hemoglobin, fasting blood glucose and total cholesterol, physical measurements such as weight and blood pressure, and questionnaire data including family history and smoking status.
The analysis is presented as a score from 0 to 100 broken down into five risk groups, and the main factors affecting the risk level are provided alongside it in order of contribution.
Whereas existing cerebrovascular AI technologies have mainly assisted in reading images that have already been taken, this program focuses on identifying in advance, before the imaging stage, those who need a detailed examination.
It is not intended to replace imaging studies themselves or to make a final diagnosis, however; it serves as key reference material for judging whether detailed examination is needed.
St. Peter's Hospital also focused on building a system for prompt referral to care after the analysis, since screening for at-risk groups has to lead to actual detailed examination and treatment for early detection to be effective.
The hospital is equipped with advanced imaging systems including 3.0T MRI and 640-channel MDCT, so patients identified as high-risk can undergo a detailed cerebrovascular examination on site immediately to determine whether a cerebral aneurysm is present and its location and size.
Yoon, Kangjun, President of St. Peter's Hospital, said, “With the introduction of this AI solution, we have completed an in-hospital process in which screening information flows seamlessly into detailed examination and treatment.”
He added, “We will continue to advance our clinical capabilities so that we can not only treat disease after onset but also prevent it in advance.”